Advertisement
This new research agreement is the second collaboration agreement signedbetween Genentech and NMS in less than twelve months.
The two Companies will collaborate in the discovery of antibody drugconjugates for the development of potential anticancer agents.
Advertisement
Genentech, which is a leading oncology company in the United States, willhave the exclusive license to fully develop and commercialize licensedproducts that contain such antibody drug conjugates.
During the research program, NMS will be primarily responsible forsynthesizing and manufacturing drug reagents, while Genentech will generateantibody drug conjugates with such drug reagents and further evaluate theirpotential therapeutic utility.
Terms of the multi-year collaboration include an initialone-time-license-fee, milestones and royalties for licensed products as wellas milestones on a target-by-target basis. Further details and financialterms were not disclosed.
"This new agreement marks an additional achievement in our strategicalliances strategy and we are very excited about the prospect of expandingour collaboration with Genentech one of the world's leading biotechcompanies," said Umberto Rosa, President of Nerviano Medical Sciences. "Webelieve that by working together and applying our complementary world classresearch capabilities in biologics and in small molecules, we may developinnovative targeted products for patients suffering from cancer."
"With this new collaboration we are very pleased to enhance ourcollaboration with Genentech and to extend it in the field of antibody drugconjugates, an area where biologics and small molecules meet to generate verypotent targeted therapies," added Giampiero Duglio, CEO of NMS. "I believethat Nerviano's expertise in the discovery of potent small molecules maycontribute to innovative and valuable products for the oncology market."
Nerviano Medical Sciences (http://www.nervianoms.com)
Nerviano Medical Sciences is the largest R&D cancer drug stand aloneCompany in Europe wholly owned by the Rome-based Congregazione dei Figlidell'Immacolata Concezione.
NMS leverages on strategic alliances with biotechnology andpharmaceutical companies for the discovery and development of innovativecancer therapies for securing long-term sustainability of the business.
NMS has already in place collaborations with Genentech Inc. and othermajor pharmaceutical companies such as Pfizer Inc. and BMS Co. as well aswith biotech- companies and academia.For more information: Nerviano Medical Sciences Maria D'Acquino Phone +39-0331-581013 - mobile +39-335-18-63-052 Email [email protected]
SOURCE Nerviano Medical Sciences
